Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour

• Published in: The international journal of neuropsychopharmacology 2014-06, Vol.17 (6), p.917-928
• Main Authors: Gibney, Sinead M., Fagan, Eimear M., Waldron, Ann-Marie, O‘Byrne, Jordan, Connor, Thomas J., Harkin, Andrew
• Format: Article
• Language: English
• Subjects: Allopurinol - pharmacology; Animals; Antidepressive Agents - pharmacology; Cerebral Cortex - drug effects; Cerebral Cortex - enzymology; Chronic Disease; Corticosterone - blood; Depressive Disorder - drug therapy; Depressive Disorder - enzymology; Disease Models, Animal; Enzyme Inhibitors - pharmacology; Kynurenine - blood; Liver - drug effects; Liver - enzymology; Male; Neuropsychological Tests; Rats, Sprague-Dawley; Restraint, Physical; RNA, Messenger - metabolism; Stress, Psychological - drug therapy; Stress, Psychological - enzymology; Tryptophan - blood; Tryptophan Oxygenase - antagonists & inhibitors; Tryptophan Oxygenase - metabolism; Weight Gain - drug effects
• ISSN: 1461-1457; 1469-5111
• DOI: 10.1017/S1461145713001673

The role of hepatic tryptophan 2,3 dioxygenase (TDO) was assessed in the provocation of stress-induced depression-related behaviour in the rat. TDO drives tryptophan metabolism via the kynurenine pathway (KP) and leads to the production of neuroactive metabolites including kynurenine. A single 2 h period of restraint stress in adult male Sprague–Dawley rats provoked an increase in circulating concentrations of the glucocorticoid corticosterone and induction of hepatic TDO expression and activity. Repeated exposure to stress (10 d of 2 h restraint each day) provoked an increase in immobility in the forced swimming test (FST) indicative of depression-related behaviour. Immobility was accompanied by an increase in the circulating corticosterone concentrations, expression and activity of hepatic TDO and increase in the expression of TDO in the cerebral cortex. Increased TDO activity was associated with raised circulating kynurenine concentrations and a reduction in circulating tryptophan concentrations indicative of KP activation. Co-treatment with the TDO inhibitor allopurinol (20 mg/kg, i.p.), attenuated the chronic stress-related increase in immobility in the FST and the accompanying increase in circulating kynurenine concentrations. These findings indicate that stress-induced corticosterone and consequent activation of hepatic TDO, tryptophan metabolism and production of kynurenine provoke a depression-related behavioural phenotype. Inhibition of stress-related hepatic TDO activity promotes antidepressant activity. TDO may therefore represent a promising target for the treatment of depression associated with stress-related disorders in which there is evidence for KP activation.